Orgenesis Spotlighted in August 2012 Issue of Drug Discovery News
Describes Plan to Treat Diabetes Using Autologous Cell Replacement
WHITE PLAINS, N.Y.-- Orgenesis Inc. (OTCBB: ORGS) (“Orgenesis” or “the Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, is one of several companies spotlighted in the August 2012 issue of Drug Discovery News in a special report about regenerative medicine.
The article, “Regenerating interest in stem cell medicine,” reports that Orgenesis is focusing its efforts on treatment for Type 1 diabetes. It notes that the company is concentrating on the conversion of autologous liver cells into insulin-producing cells that could be reimplanted in the liver to essentially replace the missing functions of the pancreas. The article also reports that Orgenesis, which is in the preclinical proof-of-concept phase, has initiated conversations with regulators about proceeding to clinical trial.
To read the article in its entirety, please visit the following link: http://www.drugdiscoverynews.com/index.php?newsarticle=6421
About Orgenesis Inc.
Orgenesis (ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to retain key employees and our ability to finance development or satisfy the rigorous regulatory requirements for new medical procedures. Competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
On Behalf of the Board
Vered Caplan, Chairperson
Source: Orgenesis Inc.
Released September 27, 2012